Literature DB >> 12390307

Nasal administration of CTB-insulin induces active tolerance against autoimmune diabetes in non-obese diabetic (NOD) mice.

C Aspord1, C Thivolet.   

Abstract

Nasal administration of beta cell-derived auto-antigens has been reported to suppress the development of autoimmune diabetes. We investigated the tolerogenic effects of insulin conjugated to the B subunit of cholera toxin (CTB). Nasal administration of 1 micro g of CTB-insulin significantly delayed the incidence of diabetes in comparison to CTB treated mice. However, administration of 4 or 8 micro g of the conjugate had no protective effect. Protection induced by CTB-insulin was transferred to naive recipients by splenic CD4+ T cells. This result favours an active cellular mechanism of regulation, which was lost using higher (4-8 micro g) or lower (0.1-0.5 micro g) amounts of the conjugate. When co-administered with diabetogenic T cells, splenic T cells from CTB-insulin-treated mice reduced the lymphocytic infiltration of the islets. Reverse transcription-polymerase chain reaction analysis of recipients' pancreatic glands revealed an increase of TGF-beta and IL-10 transcripts after donor mice tolerization, while levels of IFN-gamma and IL-4 RNAs were unchanged. We observed a significant increase of T cell proliferation after unspecific stimulation in the spleen and pancreatic lymph nodes 24 h after CTB-insulin administration in -comparison to control treatment. Higher amounts of IL-4 and IFN-gamma were noticed in pancreatic lymph nodes of tolerized mice upon in vitro stimulation. Antigen-specific unresponsiveness after immunization and upon subsequent in vitro exposure to homologous antigen was obtained in nasally treated animals. Our results underlined the importance of nasal mucosa as an inducing site of tolerance and provided evidence for similar mechanisms of action to what has been described for the oral route, which favoured a CTB-insulin specific effect.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12390307      PMCID: PMC1906515          DOI: 10.1046/j.1365-2249.2002.01988.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  40 in total

1.  Mechanisms of nasal tolerance induction in experimental autoimmune myasthenia gravis: identification of regulatory cells.

Authors:  F D Shi; H Li; H Wang; X Bai; P H van der Meide; H Link; H G Ljunggren
Journal:  J Immunol       Date:  1999-05-15       Impact factor: 5.422

2.  Suppression of collagen-induced arthritis by oral or nasal administration of type II collagen.

Authors:  G Garcia; Y Komagata; A J Slavin; R Maron; H L Weiner
Journal:  J Autoimmun       Date:  1999-11       Impact factor: 7.094

3.  Kinetics of peptide uptake and tissue distribution following a single intranasal dose of peptide.

Authors:  B Metzler; S M Anderton; S P Manickasingham; D C Wraith
Journal:  Immunol Invest       Date:  2000-02       Impact factor: 3.657

4.  Antigen-specific modulation of experimental myasthenia gravis: nasal tolerization with recombinant fragments of the human acetylcholine receptor alpha-subunit.

Authors:  D Barchan; M C Souroujon; S H Im; C Antozzi; S Fuchs
Journal:  Proc Natl Acad Sci U S A       Date:  1999-07-06       Impact factor: 11.205

5.  Regulatory Th2-type T cell lines against insulin and GAD peptides derived from orally- and nasally-treated NOD mice suppress diabetes.

Authors:  R Maron; N S Melican; H L Weiner
Journal:  J Autoimmun       Date:  1999-06       Impact factor: 7.094

Review 6.  Gamma delta T cells as mediators of mucosal tolerance: the autoimmune diabetes model.

Authors:  A Hänninen; L C Harrison
Journal:  Immunol Rev       Date:  2000-02       Impact factor: 12.988

7.  Differential activities of immunogenic collagen type II peptides in the induction of nasal tolerance to collagen-induced arthritis.

Authors:  C Q Chu; M Londei
Journal:  J Autoimmun       Date:  1999-02       Impact factor: 7.094

8.  Intranasal immunization with cytotoxic T-lymphocyte epitope peptide and mucosal adjuvant cholera toxin: selective augmentation of peptide-presenting dendritic cells in nasal mucosa-associated lymphoid tissue.

Authors:  A Porgador; H F Staats; Y Itoh; B L Kelsall
Journal:  Infect Immun       Date:  1998-12       Impact factor: 3.441

9.  Decrease of LFA-1 is associated with upregulation of TGF-beta in CD4(+) T cell clones derived from rats nasally tolerized against experimental autoimmune myasthenia gravis.

Authors:  B G Xiao; G X Zhang; F D Shi; C G Ma; H Link
Journal:  Clin Immunol Immunopathol       Date:  1998-12

10.  Cholera toxin suppresses interleukin (IL)-12 production and IL-12 receptor beta1 and beta2 chain expression.

Authors:  M C Braun; J He; C Y Wu; B L Kelsall
Journal:  J Exp Med       Date:  1999-02-01       Impact factor: 14.307

View more
  29 in total

Review 1.  Treg vaccination with a strong-agonistic insulin mimetope.

Authors:  Benno Weigmann; Carolin Daniel
Journal:  Curr Diab Rep       Date:  2012-10       Impact factor: 4.810

2.  Cytokine profile and insulin antibody IgG subclasses in patients with recent onset type 1 diabetes treated with oral insulin.

Authors:  L Monetini; M G Cavallo; E Sarugeri; F Sentinelli; L Stefanini; E Bosi; R Thorpe; P Pozzilli
Journal:  Diabetologia       Date:  2004-10-22       Impact factor: 10.122

3.  Myeloperoxidase Peptide-Based Nasal Tolerance in Experimental ANCA-Associated GN.

Authors:  Poh-Yi Gan; Diana S Y Tan; Joshua D Ooi; Maliha A Alikhan; A Richard Kitching; Stephen R Holdsworth
Journal:  J Am Soc Nephrol       Date:  2015-06-05       Impact factor: 10.121

4.  Active immunization using a single dose immunotherapeutic abates established EAE via IL-10 and regulatory T cells.

Authors:  Agnieszka Rynda-Apple; Eduardo Huarte; Massimo Maddaloni; Gayle Callis; Jerod A Skyberg; David W Pascual
Journal:  Eur J Immunol       Date:  2010-12-29       Impact factor: 5.532

Review 5.  Extra-thymically induced regulatory T cells: do they have potential in disease prevention?

Authors:  Carolin Daniel; Harald von Boehmer
Journal:  Semin Immunol       Date:  2011-07-02       Impact factor: 11.130

6.  Inducing immune tolerance: a focus on Type 1 diabetes mellitus.

Authors:  Dan Xu; Suchitra Prasad; Stephen D Miller
Journal:  Diabetes Manag (Lond)       Date:  2013-09-01

7.  IL-10/TGF-beta-treated dendritic cells, pulsed with insulin, specifically reduce the response to insulin of CD4+ effector/memory T cells from type 1 diabetic individuals.

Authors:  Honorio Torres-Aguilar; Carmen Sánchez-Torres; Luis J Jara; Miri Blank; Yehuda Shoenfeld
Journal:  J Clin Immunol       Date:  2010-06-11       Impact factor: 8.317

8.  Autoantigens plus interleukin-10 suppress diabetes autoimmunity.

Authors:  Béla Dénes; István Fodor; William H R Langridge
Journal:  Diabetes Technol Ther       Date:  2010-08       Impact factor: 6.118

9.  Virtual optimization of nasal insulin therapy predicts immunization frequency to be crucial for diabetes protection.

Authors:  Georgia Fousteri; Jason R Chan; Yanan Zheng; Chan Whiting; Amy Dave; Damien Bresson; Michael Croft; Matthias von Herrath
Journal:  Diabetes       Date:  2010-09-23       Impact factor: 9.461

10.  IL-28 supplants requirement for T(reg) cells in protein sigma1-mediated protection against murine experimental autoimmune encephalomyelitis (EAE).

Authors:  Agnieszka Rynda; Massimo Maddaloni; Javier Ochoa-Repáraz; Gayle Callis; David W Pascual
Journal:  PLoS One       Date:  2010-01-14       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.